What We Do
- ACT brings together hundreds of researchers from 28 networks, 11 trial units, patient-partners, the biotechnology industry, government, and experts in research ethics review processes, contracts, insurance, regulatory processes, patient engagement, clinical trials training, communications, knowledge mobilization – from Nova Scotia to British Columbia and Nunavut.
- ACT will maximize research impact and knowledge mobilization – following best practices in patient-oriented research and integrated knowledge translation, leveraging national and international contacts.
- ACT will advance equitable access to trials for all Canadians – no matter where they live, inclusive of gender, ethnicity, and socioeconomic status – following the principles of equity, diversity, and inclusion in clinical trials such that the knowledge gained is applicable to all those affected.
- ACT will build clinical trial capacity – providing trial units with the knowledge, skills, and experience to conduct large-scale trials. We will streamline administrative processes (for example, ethics reviews, contracts, and protocols) to accelerate timelines and reduce costs.
Who We Are
ACT Operating Committee (AOC)
Patient Engagement Committee
Manuel Escoto is the Patient, Family, and Donor Partnerships & Education Manager with The Canadian Donation and Transplantation Research Program (CDTRP). Within CDTRP, Manuel supports the integration of patient, family, and donor (PFD) partners into research projects and in CDTRP’s governance and leadership activities. He also leads CDTRP’s patient engagement capacity-building activities. Before joining CDTRP, Manuel was the Community Development and Communications Manager with The Kidney Foundation. In this role, he connected with patients and families impacted by kidney health, organ donation, and transplantation to help them navigate the health system. He was also responsible for educational initiatives increasing the awareness of The Kidney Foundation, kidney disease, and organ donation. As a kidney transplant recipient, he’s developed a passion for donation and transplantation policy and research and advocates for the meaningful integration of patient partners in research, policy development, and knowledge mobilization initiatives. He has a Master of Public Health and has experience developing evidence-based policy recommendations with government and community-based research organizations.
Alicia Murdoch is a certified Clinical Research Professional (ACRP-CP) with over 14 years of clinical research experience. Prior to joining Can-SOLVE CKD, she worked as a research coordinator, review manager at a Research Ethics Board (REB) and ethics and regulatory coordinator for phase 2 and 3 clinical trials. Her past employment experiences have given her a wide breadth of knowledge about the research process. In her current role as a Can-SOLVE CKD Network project manager, she is responsible for the Canadian Nephrology Trials Network and Can-SOLVE CKD Network Pediatric Committee, helping these core infrastructures move their initiatives and ideas forward in the pursuit of improving the lives of those affected by chronic kidney disease.
ACT Coordinating Centre
Dr. Salim Yusuf is Executive Director of the ACT Coordinating Centre, PHRI, and a principal applicant of the ACT consortium. He has led >50 major RCTs in >100 countries and several of these have changed medical practice worldwide. He has published >1200 articles in refereed journals, he was the second most cited researcher in the world in 2011, and the highest cited researcher in cardiology for several years. He is the highest cited scientist in the world for clinical trials, 8th in all fields of medicine combined, 2nd in Canada, and has the 17th highest h-index (267) globally. He has set standards for large simple trials, and has established a network for clinical trials at >1000 centres in >60 countries. He has received >70 awards including the Order of Canada, Gairdner-Wightman Award, Killam Prize, Canadian Medical Hall of Fame, Gold Medal of the Royal Society of Canada, and awards from many major international cardiology societies including the World Heart Federation’s Lifetime Research Achievement Award. He has served on advisory committees for the US FDA, and has obtained regulatory approvals based on his research for new drugs in Canada, the US, the UK, and Europe.